RxDoctor Payments Data

Angele Seiler, MD

Internal Medicine · Arlington, VANPI 1265493969

Payments from drug & device makers

$736in general payments, 2019–2025

Across 18 payments — averaging $40.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Idorsia Pharmaceuticals US Inc$123
  • Abbott$122
  • Novo Nordisk$112
  • Merck$111
  • Pfizer$84
  • AbbVie$57
  • plus $127 from 7 others

What the payments were for

  • Food & beverage$71998%
  • Education$172%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$736 in reported general payments places this provider in the 70th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$145,238
Medicare patients
268
Services billed
1,603

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban29$36,011
MounjaroTirzepatide19$22,460
RybelsusSemaglutide16$19,605
OzempicSemaglutide11$10,638
MyrbetriqMirabegron13$10,200
JanuviaSitagliptin Phosphate20$8,380
GemtesaVibegron13$6,118
SynthroidLevothyroxine Sodium57$5,583
Estradiol27$5,075
Rosuvastatin Calcium247$4,317
Bupropion XlBupropion Hcl42$2,415
Duloxetine Hcl95$2,383
Levothyroxine Sodium177$2,061
Irbesartan71$1,743
Valsartan45$1,680

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$84$36,01129 claims
Novo NordiskRybelsus, Ozempic$112$30,24327 claims
MerckJanuvia$111$8,38020 claims
AbbVieSynthroid$57$5,58357 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Arlington

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →